ABSTRACT
@#【Objective】To investigate the effect of cinnamaldehyde on the apoptosis of RL95- 2 cell in endometrial carcinoma. 【Methods】 Endometrial carcinoma RL95- 2 cells were treated with cinnamaldehyde，and the proliferation activity and IC50 of endometrial carcinoma RL95-2 cells were detected by MTT colorimetry assay. Apoptotic morphology was observed after Hoechst 33258 staining. The percentage of apoptosis in RL95-2 cells was measured by flow cytometry. Western blot analysis was used to test the effect of cinnamaldehyde on the expression of Cleaved caspase- 3，caspase-3， NF-κB·p65，IL-6 and IGF-R in RL95-2 cells.【Results】Cinnamaldehyde can reduce the viability rate of endometrial cancer RL95- 2 cells，which is related to the treatment duration and concentration. Compared with the solvent control group， the apoptosis percentage of RL95- 2 cells in the cinnamaldehyde group （0.29， 0.59， 1.20 mg/mL） was significantly increased after 48 hours（P < 0.01），typical apoptotic bodies were found ，and the expression of Cleaved caspase-3 protein was significantly increased（P < 0.01），there was no significant change in the expression of Caspase 3 protein（P > 0.05），while the expression of NF- κB · p65，IL- 6 and IGF- R protein were significantly increased（P <0.05）.【Conclusion】Cinnamaldehyde can reduce the expression of NF-κB·p65，IL-6 and IGF-R proteins in RL95-2 cells and promote the apoptosis of RL95-2 cells，thus playing an anti-endometrial cancer role.
ABSTRACT
The primary function of insulin is viewed as a hormone that controls blood glucose level. However, there is growing evidence that aberrant insulin level and insulin-mediated signaling can lead to cancer development and progression. The insulin-cancer relationship has stemmed from various observational and epidemiological studies, which linked higher incidence of cancer with central obesity, type II diabetes and other conditions associated with increased levels of circulating insulin, insulin resistance and hyperinsulinemic states. Increased risk of developing a range of cancers is also seen with a certain treatment options used to lower blood glucose level in diabetic patients. While metformin monotherapy has the lowest risk of developing cancer, in comparison, treatment with insulin or insulin secretagogues shows more likelihood to develop solid cancers. Cellular signaling initiated by insulin provides a clue regarding these diverse cellular outcomes. This review discusses how the insulin enacts such diverse physiological effects and the insulin-cancer relationship, with focus on the role of insulin signaling in cancer.